Novartis has negotiated an exclusive global licencing deal with MorphoSys AG and Galapagos NV for rights to their jointly developed monoclonal antibody for atopic dermatitis, MOR106. The antibody originated in MorphoSys’ laboratories and targets interleukin-17C, a cytokine that has been shown to play an important role in inflammatory skin disorders.
